Repatha
Product Images NDC 72511-770

111 FDA label images from Amgen Usa Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 111 technical images submitted to the FDA as part of the official labeling for Repatha (NDC 72511-770). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Amgen Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 1 (Repatha Amgenusa 01)

Figure 1 (Repatha Amgenusa 01)
A line graph showing cumulative incidence (%) over 36 months comparing REPATHA and placebo. The REPATHA group (red dashed line) consistently shows a lower cumulative incidence than the placebo group (blue solid line). The x-axis represents months, and the y-axis represents cumulative incidence percentage. Below the graph is a table indicating the number of patients at risk for both groups at various time points.*
FDA Label Image

Figure 2 (Repatha Amgenusa 02)

Figure 2 (Repatha Amgenusa 02)
A cumulative incidence line graph comparing REPATHA 140 mg/mL and placebo over 36 months. The x-axis shows time in months, and the y-axis shows cumulative incidence percentage. REPATHA is represented by a red dashed line, consistently showing lower incidence compared to the blue solid line for placebo. The number of patients at risk is indicated below the graph for both groups at multiple time points.*
FDA Label Image

Figure 3 (Repatha Amgenusa 02a)

Figure 3 (Repatha Amgenusa 02a)
A line graph showing cumulative incidence percentage over 66 months comparing two groups: placebo (blue solid line) and Repatha (red dashed line). The x-axis represents months, and the y-axis represents cumulative incidence (%). Patient counts at risk are displayed at various time points below the x-axis for both groups.*
FDA Label Image

Figure 4 (Repatha Amgenusa 02b)

Figure 4 (Repatha Amgenusa 02b)
A line graph showing cumulative incidence percentages over time in months for two groups: Placebo (solid blue line) and Repatha (dashed red line). The x-axis represents months from 0 to 66, and the y-axis shows cumulative incidence from 0 to 18%. Patient counts at risk are displayed below the x-axis for both groups at multiple time points.*
FDA Label Image

Figure 5 (Repatha Amgenusa 02c)

Figure 5 (Repatha Amgenusa 02c)
A line chart showing cumulative incidence percentage over months for two groups, Placebo (blue solid line) and Repatha (red dotted line). The x-axis represents months (0 to 66), and the y-axis represents cumulative incidence in percentage (0 to 18%). Numbers of patients at risk for both groups are displayed below the x-axis at each time interval.*
FDA Label Image

Figure 6 (Repatha Amgenusa 03)

Figure 6 (Repatha Amgenusa 03)
A comparative bar chart illustrating treatment differences in percent change from baseline LDL-C levels. The chart compares REPATHA 140 mg every 2 weeks and 420 mg once monthly against placebo across several statins and against ezetimibe with atorvastatin at varying dosages. The vertical axis measures percent change in LDL-C, ranging from 0 to -100%. The chart highlights effectiveness of REPATHA administered at different dosing schedules in combination or comparison with statin types and dosages.*
FDA Label Image

Figure 7 (Repatha Amgenusa 04)

Figure 7 (Repatha Amgenusa 04)
A line graph comparing the percent change from baseline over 52 weeks between REPATHA 420 mg once monthly and placebo once monthly. The y-axis shows percent change from baseline, and the x-axis marks time points at baseline, week 12, 24, 36, and 52. REPATHA shows a marked decrease in percent change compared to placebo. Sample sizes for each group at each time point are indicated below the x-axis.*
FDA Label Image

Figure 8 (Repatha Amgenusa 05)

Figure 8 (Repatha Amgenusa 05)
A line graph showing percent change from baseline over 12 weeks for four groups: Placebo every 2 weeks, REPATHA 140 mg every 2 weeks, Placebo once monthly, and REPATHA 420 mg once monthly. The chart includes data points at baseline, weeks 2, 8, 10, and 12 with observed sample sizes for each group indicated. REPATHA groups show significant decreases over time compared to placebo groups, which remain near baseline values.*
FDA Label Image

Figure 9 (Repatha Amgenusa 06)

Figure 9 (Repatha Amgenusa 06)
A line graph depicting percent change from baseline over a 24-week study period, comparing two groups: Placebo QM (N=53) and EvoMab 420 mg QM (N=104). The x-axis represents study weeks (Baseline, Week 12, Week 24), and the y-axis shows percent change from baseline. The Placebo group shows minimal change, while the EvoMab group shows a sharp reduction at Week 12 that remains stable through Week 24. Error bars indicate variability for each time point.*
FDA Label Image

Image (Repatha Amgenusa 42)

Image (Repatha Amgenusa 42)
An instructional diagram of a REPATHA 140 mg/mL injection pen by Amgen USA Inc. It labels key parts of the pen, including a gray start button at the top, an expiration date area, a window showing the medicine inside, and an orange cap with a yellow safety guard covering the needle at the bottom.*
FDA Label Image

Image (Repatha Amgenusa 43)

Image (Repatha Amgenusa 43)
Illustration diagram of a REPATHA 140 mg/mL prefilled pen by Amgen USA Inc., showing labeled parts including expiration date, yellow window indicating injection completion, yellow safety guard covering the needle, and an orange cap that should be removed before use.*
FDA Label Image

Image (Repatha Amgenusa 44)

Image (Repatha Amgenusa 44)
An illustration of a clock face showing 30 minutes in red, indicating a half-hour time period. The image is a simple graphic with half of the clock shaded and the text '30 minutes' displayed within the shaded area.*
FDA Label Image

Image (Repatha Amgenusa 45)

Image (Repatha Amgenusa 45)
Illustration showing a REPATHA prefilled syringe with labeled parts: orange cap on, yellow safety guard containing the needle, a window displaying the medicine inside.*
FDA Label Image

Image (Repatha Amgenusa 46)

Image (Repatha Amgenusa 46)
Illustration showing administration and disposal items for REPATHA 140 mg/mL. It includes a blue prefilled autoinjector pen, medication dosage cards or labels, three white round tablets, a beige adhesive bandage, and a red biohazard sharps container for safe disposal of used injection devices.*
FDA Label Image

Image (Repatha Amgenusa 47)

Image (Repatha Amgenusa 47)
An anatomical illustration highlighting recommended injection sites for REPATHA 140 mg/mL. The diagram shows shaded areas on the upper arm, stomach, and thigh, each labeled accordingly to indicate suitable locations for administering the medication.*
FDA Label Image

Image (Repatha Amgenusa 48)

Image (Repatha Amgenusa 48)
An instructional illustration showing hands removing the orange cap from a REPATHA 140 mg/mL prefilled pen injector, demonstrating the first step in preparing the device for use.*
FDA Label Image

Image (Repatha Amgenusa 49)

Image (Repatha Amgenusa 49)
An illustration of a clock face showing a time span of five minutes, highlighted by a shaded red segment representing the duration. The number '5 minutes' is displayed under the clock.*
FDA Label Image

Image (Repatha Amgenusa 50)

Image (Repatha Amgenusa 50)
An instructional illustration showing a hand with two fingers pinching a fold of skin on the arm. Two black arrows point opposite directions along the skin fold, indicating a technique, likely related to drug administration.*
FDA Label Image

Image (Repatha Amgenusa 51)

Image (Repatha Amgenusa 51)
Instructional illustration showing how to pinch the skin on the arm with one hand while holding a syringe with the other hand. The arrows indicate the motion of pinching and insertion for an injection.*
FDA Label Image

Image (Repatha Amgenusa 52)

Image (Repatha Amgenusa 52)
An instructional diagram illustrating the correct subcutaneous injection technique for REPATHA 140 mg/mL. It shows a hand holding the injection device at a 90-degree angle to the skin, with a close-up highlighting the yellow safety guard covering the needle.*
FDA Label Image

Image (Repatha Amgenusa 53)

Image (Repatha Amgenusa 53)
An instructional illustration showing a hand holding a REPATHA 140 mg/mL injection pen, with an arrow indicating the injection direction into the skin, while another hand stabilizes the injection site. The image demonstrates the proper technique for administering a subcutaneous injection using the pen.*
FDA Label Image

Image (Repatha Amgenusa 54)

Image (Repatha Amgenusa 54)
An instructional illustration showing hands administering an injection using a REPATHA 140 mg/mL auto-injector. One hand holds the auto-injector perpendicular to the skin, while the other supports the injection site. An arrow indicates downward motion and a 'click' sound is highlighted to signal proper activation.*
FDA Label Image

Image (Repatha Amgenusa 55)

Image (Repatha Amgenusa 55)
Instructional illustration showing how to use the REPATHA 140 mg/mL autoinjector. It depicts a hand holding the autoinjector upright against the skin, with an arrow indicating downward pressure to activate the injection, accompanied by a 'click' sound to confirm activation.*
FDA Label Image

Image (Repatha Amgenusa 56)

Image (Repatha Amgenusa 56)
An illustration showing a timer set to 15 seconds above a test strip device with a yellow central indicator area, likely representing a timing step in an assay or test procedure.*
FDA Label Image

Image (Repatha Amgenusa 57)

FDA Label Image

Image (Repatha Amgenusa 58)

Image (Repatha Amgenusa 58)
An instructional illustration showing a hand disposing of a used REPATHA 140 mg/mL autoinjector pen into a red sharps disposal container marked with a biohazard symbol. The image highlights safe disposal of the injection device after use.*
FDA Label Image

Image (Repatha Amgenusa 58a)

Image (Repatha Amgenusa 58a)
Instructional illustration showing how to open the top of a round container and a pen-like device with a yellow tip and an orange cap, likely related to medication administration or injection preparation.*
FDA Label Image

Image (Repatha Amgenusa 59)

Image (Repatha Amgenusa 59)
An instructional diagram of a REPATHA 140 mg/mL autoinjector pen by Amgen USA Inc. The illustration labels parts of the pen, including a gray start button, expiration date area, a transparent window showing the medicine inside, an orange cap, and a yellow safety guard covering the needle.*
FDA Label Image

Image (Repatha Amgenusa 60)

Image (Repatha Amgenusa 60)
An instructional diagram showing recommended injection sites on a human body for a medication. The labeled areas include the upper arm, stomach, and thigh, indicating where injections can be administered.*
FDA Label Image

Image (Repatha Amgenusa 61)

Image (Repatha Amgenusa 61)
An instructional illustration showing how to insert a cartridge into a REPATHA pen injector. One hand holds the pen, while the other hand is placing the cartridge into the pen, indicated by a left-pointing arrow.*
FDA Label Image

Image (Repatha Amgenusa 62)

Image (Repatha Amgenusa 62)
An illustration of a clock face showing a 5-minute interval shaded in red, with the text '5 minutes' inside the clock. This image likely serves as an instructional graphic related to timing or wait period for the use of the REPATHA 140 mg/mL product by Amgen USA Inc.*
FDA Label Image

Image (Repatha Amgenusa 63)

Image (Repatha Amgenusa 63)
An instructional illustration showing a hand performing the 'stretch method' on the skin, indicating a left-right stretch motion with arrows. The text 'Stretch method:' labels the instruction.*
FDA Label Image

Image (Repatha Amgenusa 64)

Image (Repatha Amgenusa 64)
An instructional illustration showing a hand holding a REPATHA 140 mg/mL prefilled syringe with a yellow safety guard indicating the needle is inside. An inset zoom highlights the correct position of the yellow safety guard on the syringe.*
FDA Label Image

Image (Repatha Amgenusa 65)

Image (Repatha Amgenusa 65)
An instructional illustration showing the 'Pinch method' for injection. It depicts a hand pinching the skin with arrows indicating where to pinch and the direction of the pinch. The text 'Pinch method:' is shown to the left of the image.*
FDA Label Image

Image (Repatha Amgenusa 66)

Image (Repatha Amgenusa 66)
An instructional illustration showing the proper technique for administering an injection using a Repatha autoinjector pen. It depicts one hand holding the 140 mg/mL Repatha pen vertically against the skin while the other hand stabilizes the injection site, with an arrow indicating pressing down until a 'click' sound is heard.*
FDA Label Image

Image (Repatha Amgenusa 67)

Image (Repatha Amgenusa 67)
An instructional illustration showing a timer set to 15 seconds next to a vertical device with a yellow indicator bar, likely demonstrating part of the administration or preparation process for a medication injection.*
FDA Label Image

Figure (Repatha Amgenusa 68)

Figure (Repatha Amgenusa 68)
An instructional illustration showing a hand holding a REPATHA 140 mg/mL pen and pressing it perpendicularly onto the skin to administer the injection, indicated by a downward arrow and a 'click' sound graphic.*
FDA Label Image

Figure (Repatha Amgenusa 69)

Figure (Repatha Amgenusa 69)
An instructional diagram labeling parts of a syringe containing medicine, including the plunger rod, medicine inside the syringe barrel, and a gray needle cap on the end. This illustration is relevant to the REPATHA 140 mg/mL injectable product by Amgen USA Inc.*
FDA Label Image

Figure (Repatha Amgenusa 70)

Figure (Repatha Amgenusa 70)
An instructional diagram showing components of a used syringe assembly for REPATHA 140 mg/mL. The image labels the used plunger, used syringe barrel, and used needle, along with a separate gray needle cap removed from the needle.*
FDA Label Image

Figure (Repatha Amgenusa 71)

Figure (Repatha Amgenusa 71)
An illustration of a clock face showing a 30-minute interval highlighted in red on the right half, with the text '30 minutes' displayed within the red section.*
FDA Label Image

Figure (Repatha Amgenusa 72)

Figure (Repatha Amgenusa 72)
An instructional illustration showing a prefilled syringe on the left and several medical items on the right, including alcohol pads, cotton balls, an adhesive bandage, and a red biohazard sharps disposal container. The image likely depicts supplies related to administering an injection.*
FDA Label Image

Figure (Repatha Amgenusa 73)

Figure (Repatha Amgenusa 73)
An instructional diagram showing the recommended injection sites for REPATHA 140 mg/mL. The shaded areas on a human body outline include the upper arms, stomach area, and thighs. Each location is labeled accordingly, indicating where the medication can be administered subcutaneously.*
FDA Label Image

Figure (Repatha Amgenusa 74)

Figure (Repatha Amgenusa 74)
Instructional illustration showing a person preparing to inject REPATHA by cleaning the abdominal area with an alcohol swab before administration. The image demonstrates proper skin preparation prior to injection.*
FDA Label Image

Figure (Repatha Amgenusa 75)

Figure (Repatha Amgenusa 75)
An instructional illustration showing four sequential steps for using a syringe. The first step shows a hand holding a syringe in a transparent tray. The second step shows turning the tray over to release the syringe. The third step shows gently pressing the tray to free the syringe. The fourth step shows the syringe held in the palm of a hand, ready for use.*
FDA Label Image

Figure (Repatha Amgenusa 75a)

Figure (Repatha Amgenusa 75a)
Instructional illustration showing the steps to open a vial cap and attach a needle or syringe, likely related to the preparation of the REPATHA 140 mg/mL injection.*
FDA Label Image

Figure (Repatha Amgenusa 76)

Figure (Repatha Amgenusa 76)
An instructional diagram of a prefilled syringe labeled REPATHA 140 mg/mL by Amgen USA Inc. The illustration identifies key syringe components: plunger rod, syringe barrel, medicine inside the barrel, syringe label with expiration date, and a gray needle cap on the needle end.*
FDA Label Image

Figure (Repatha Amgenusa 77)

Figure (Repatha Amgenusa 77)
An instructional illustration showing two hands preparing a syringe. The top hand is pulling upward on a component, while the bottom hand holds the syringe steady, indicating a step in medication preparation or administration.*
FDA Label Image

Figure (Repatha Amgenusa 78)

Figure (Repatha Amgenusa 78)
An instructional illustration showing a hand dropping a used cartridge into a red biohazard sharps container with a flip-top lid. The container features a biohazard symbol, indicating safe disposal of medical sharps.*
FDA Label Image

Figure (Repatha Amgenusa 79)

Figure (Repatha Amgenusa 79)
An instructional illustration showing a hand pinching the skin on the arm. Two black arrows indicate the direction of pinching and motion, likely demonstrating how to properly prepare an injection site or administer an injection.*
FDA Label Image

Figure (Repatha Amgenusa 80)

Figure (Repatha Amgenusa 80)
Instructional illustration showing a hand holding a syringe perpendicular (90 degrees) to the skin surface, indicating the correct injection angle between 45 and 90 degrees for administering a subcutaneous injection.*
FDA Label Image

Figure (Repatha Amgenusa 81)

Figure (Repatha Amgenusa 81)
An instructional illustration showing a hand administering a subcutaneous injection with a syringe into another person's skin. The syringe is positioned perpendicular to the skin surface with an arrow pointing downward onto the plunger to indicate pressing it.*
FDA Label Image

Figure (Repatha Amgenusa 82)

Figure (Repatha Amgenusa 82)
An instructional illustration showing a hand pulling an injection syringe out of skin, depicting the step of removing the needle after administering a subcutaneous injection.*
FDA Label Image

Figure (Repatha Amgenusa 83)

Figure (Repatha Amgenusa 83)
An instructional illustration showing a hand holding a syringe and disposing of it into a red biohazard sharps container with an open lid. The image visually guides the proper disposal of needles or syringes.*
FDA Label Image

Figure (Repatha Amgenusa 84)

Figure (Repatha Amgenusa 84)
Repatha SureClick (evolocumab) Injection 140 mg/mL prefilled autoinjector carton by Amgen USA Inc. Contains 2 x 1 mL single-dose prefilled autoinjectors. Designed for subcutaneous use only. Label includes storage instructions and cautionary statements.*
FDA Label Image

Figure (Repatha Amgenusa 85)

Figure (Repatha Amgenusa 85)
Repatha (evolocumab) 140 mg/mL prefilled syringe label from Amgen USA Inc. The label indicates a 1 mL injection for subcutaneous use only. Storage instructions specify refrigeration at 2°C to 8°C (36°F to 46°F) and caution against freezing or shaking. The solution is sterile with no preservative and single-use only.*
FDA Label Image

Figure (Repatha Amgenusa 86)

Figure (Repatha Amgenusa 86)
The packaging label for REPATHA Pushtronex system (evolocumab) shows a 420 mg/3.5 mL strength in an on-body infusor and prefilled cartridge format. The label includes storage instructions, usage warnings, and manufacturer Amgen USA Inc. The design features text in black and red with a blue Amgen logo and an image of the infusor device.*
FDA Label Image

Figure (Repatha Amgenusa 87)

Figure (Repatha Amgenusa 87)
An illustration of a clock face highlighting a 30-minute interval in red. The number "30" and the word "minutes" are displayed within the red-highlighted portion, indicating a time duration of thirty minutes.*
FDA Label Image

Figure (Repatha Amgenusa 88)

Figure (Repatha Amgenusa 88)
Instructional illustration showing components of the REPATHA 140 mg/mL injection kit by Amgen USA Inc. Includes a prefilled syringe, three cotton balls, an alcohol prep pad, a bandage, and a red sharps disposal container with an open lid.*
FDA Label Image

Figure (Repatha Amgenusa 89)

Figure (Repatha Amgenusa 89)
An instructional diagram showing recommended injection sites on the human body labeled as upper arm, stomach, and front of thigh for administering a medication. The figure highlights these regions in shaded areas on a front view of a human figure.*
FDA Label Image

Figure (Repatha Amgenusa 90)

Figure (Repatha Amgenusa 90)
An instructional illustration depicting a person cleaning or preparing the skin around the abdominal area, likely for an injection. The image shows a hand holding a cloth or pad applying it to the skin, with a second hand holding an applicator device near the abdomen.*
FDA Label Image

Figure (Repatha Amgenusa 91)

Figure (Repatha Amgenusa 91)
Illustration showing four steps to prepare an injection: holding a prefilled syringe tray, turning the tray over, gently pressing the syringe against the skin, and the syringe needle inserted in the skin. No specific product details are visible in the image.*
FDA Label Image

Figure (Repatha Amgenusa 92)

Figure (Repatha Amgenusa 92)
Illustration of a prefilled syringe for REPATHA 140 mg/mL by Amgen USA Inc., showing labeled parts including the plunger rod, syringe barrel containing medicine, syringe label with expiration date, and gray needle cap.*
FDA Label Image

Figure (Repatha Amgenusa 93)

Figure (Repatha Amgenusa 93)
An instructional illustration showing two hands preparing an injection. One hand holds an upright vial with the thumb pushing a stopper upwards, and the other hand holds a syringe ready to draw the liquid. The image demonstrates the technique of extracting medication with a syringe from a vial, relevant for REPATHA 140 mg/mL injection preparation.*
FDA Label Image

Figure (Repatha Amgenusa 94)

Figure (Repatha Amgenusa 94)
An instructional illustration showing a hand placing a used auto-injector device into a red sharps disposal container. This indicates proper disposal of the REPATHA 140 mg/mL autoinjector after use.*
FDA Label Image

Figure (Repatha Amgenusa 95)

Figure (Repatha Amgenusa 95)
An instructional illustration showing two fingers pinching the skin of an arm, with arrows indicating the pinching action. The image likely demonstrates how to prepare the skin for a subcutaneous injection, associated with REPATHA 140 mg/mL by Amgen USA Inc.*
FDA Label Image

Figure (Repatha Amgenusa 96)

Figure (Repatha Amgenusa 96)
An instructional illustration showing two hands administering an injection with a syringe into the skin at a 45-degree angle. The image includes a small angle diagram indicating proper injection angles of 90 and 45 degrees.*
FDA Label Image

Figure (Repatha Amgenusa 97)

Figure (Repatha Amgenusa 97)
An instructional illustration showing the administration of an injection into the arm. The image depicts one hand holding a syringe and the other hand stabilizing the injection site.*
FDA Label Image

Figure (Repatha Amgenusa 98)

Figure (Repatha Amgenusa 98)
An instructional illustration showing a hand administering an injection with a syringe into the skin of the forearm. The other hand stretches the skin, and an upward arrow indicates the syringe is being pulled back after injection.*
FDA Label Image

Figure (Repatha Amgenusa 99)

Figure (Repatha Amgenusa 99)
An instructional illustration showing a hand inserting a used syringe downward into a red sharps disposal container. The image demonstrates proper disposal technique for syringes used with REPATHA 140 mg/mL.*
FDA Label Image

Figure (Repatha Amgenusa 100)

Figure (Repatha Amgenusa 100)
An instructional diagram of a syringe labeled with parts including the plunger rod, medicine inside the syringe barrel, and gray needle cap on the tip. The image highlights the components of a prefilled syringe device, typically used for injectable medications like REPATHA.*
FDA Label Image

Figure (Repatha Amgenusa 101)

Figure (Repatha Amgenusa 101)
An instructional diagram showing a used syringe with labeled parts: plunger, syringe barrel, and needle, with the gray needle cap removed. A separate component, likely a needle cap, is shown below the syringe.*
FDA Label Image

Figure (Repatha Amgenusa 102)

Figure (Repatha Amgenusa 102)
An illustration of a clock face with half the circle shaded red, indicating a 30-minute time interval. The text '30 minutes' appears within the shaded area, suggesting a time duration or waiting period.*
FDA Label Image

Figure (Repatha Amgenusa 103)

Figure (Repatha Amgenusa 103)
An illustrated step-by-step instructional diagram showing how to prepare and use the REPATHA 140 mg/mL prefilled syringe. The sequence includes removing the syringe cap, checking the solution, applying a skin alcohol swab, a patch for potential injection site care, and a disposal container for used materials. No text is shown.*
FDA Label Image

Figure (Repatha Amgenusa 104)

Figure (Repatha Amgenusa 104)
An illustration showing recommended injection sites on the human body for REPATHA 140 mg/mL. The labeled areas include the upper arm, stomach, and front of the thigh, indicating where subcutaneous injections can be administered.*
FDA Label Image

Figure (Repatha Amgenusa 105)

Figure (Repatha Amgenusa 105)
An instructional illustration showing a person preparing to inject medication into their abdomen. The person uses an alcohol prep pad to clean the injection site before administering the injection with a syringe or pen. The image depicts proper hygiene preparation for subcutaneous injection.*
FDA Label Image

Figure (Repatha Amgenusa 106)

Figure (Repatha Amgenusa 106)
Instructional illustration showing how to use the REPATHA 140 mg/mL single-dose prefilled syringe by Amgen USA Inc. The steps include holding the syringe, turning the tray over to expose it, gently pressing the syringe onto the injection site, and completing the injection with the needle inserted into the skin.*
FDA Label Image

Figure (Repatha Amgenusa 107)

Figure (Repatha Amgenusa 107)
An instructional diagram of a prefilled syringe labeled REPATHA 140 mg/mL. The diagram identifies parts of the syringe including the plunger rod, syringe barrel containing medicine, the syringe label featuring an expiration date, and a gray needle cap on the tip.*
FDA Label Image

Figure (Repatha Amgenusa 108)

Figure (Repatha Amgenusa 108)
An instructional illustration showing two hands holding a syringe and a vial. The upper hand is pulling the vial upward with an arrow indicating upward motion, while the lower hand holds the syringe, demonstrating how to draw medication from the vial.*
FDA Label Image

Figure (Repatha Amgenusa 109)

Figure (Repatha Amgenusa 109)
An instructional illustration showing a hand inserting a cap or small component into the opening of a red container or device. The image suggests proper placement or assembly, likely related to REPATHA's use or storage.*
FDA Label Image

Figure (Repatha Amgenusa 110)

Figure (Repatha Amgenusa 110)
An illustration showing a close-up of a hand pinching the side of the skin between the thumb and forefinger. Two black arrows indicate the pinching motion, one pointing down and the other up, demonstrating how to properly pinch the skin.*
FDA Label Image

Figure (Repatha Amgenusa 111)

Figure (Repatha Amgenusa 111)
An instructional illustration showing a hand holding a syringe angled at 45 degrees above a skin surface, with another hand stabilizing the skin. An inset diagram shows angle options of 90 degrees and 45 degrees for injection placement.*
FDA Label Image

Figure (Repatha Amgenusa 112)

Figure (Repatha Amgenusa 112)
An instructional illustration showing the proper technique for injecting a medication with a syringe. One hand holds the syringe vertically with the needle pointing downward, while the other hand holds the injection site on the arm.*
FDA Label Image

Figure (Repatha Amgenusa 113)

Figure (Repatha Amgenusa 113)
An instructional illustration showing a hand pulling back the plunger of a syringe held in another hand, positioned for injection. This image demonstrates the technique of preparing or administering an injection, relevant to the REPATHA 140 mg/mL drug product usage instructions.*
FDA Label Image

Figure (Repatha Amgenusa 114)

Figure (Repatha Amgenusa 114)
An instructional illustration showing a hand inserting a syringe into the top opening of a red sharps disposal container, indicating proper disposal of the syringe by pushing it downward into the container. This image is likely part of patient or healthcare provider instructions for safely discarding used syringes.*
FDA Label Image

Ifu (Repatha Amgenusa 123)

Ifu (Repatha Amgenusa 123)
Repatha 140 mg/mL prefilled pen device is shown along with the Repatha logo. The image features the injectable pen used for administration, labeled with the brand name Repatha and the labeler Amgen USA Inc.*
FDA Label Image

Ifu (Repatha Amgenusa 124)

Ifu (Repatha Amgenusa 124)
An instructional illustration showing a two-step opening procedure for a container or package. The diagram highlights the second step with a blue arrow pointing to the inner flap being revealed after opening the outer cover.*
FDA Label Image

Ifu (Repatha Amgenusa 125)

Ifu (Repatha Amgenusa 125)
An instructional diagram of the REPATHA 140 mg/mL prefilled syringe showing labeled parts including the lot and expiration date area, window to view medicine and plunger, yellow safety guard with needle inside, and cap with a note not to remove until step 6. The syringe is depicted vertically with key components annotated for proper use.*
FDA Label Image

Ifu (Repatha Amgenusa 126)

Ifu (Repatha Amgenusa 126)
An instructional illustration depicting a red sharps disposal container with a hinged lid. The image also shows three labeled items: an alcohol wipe, an adhesive bandage, and cotton balls or gauze pads, likely indicating supplies for injection site care or post-injection treatment.*
FDA Label Image

Ifu (Repatha Amgenusa 127)

FDA Label Image

Ifu (Repatha Amgenusa 128)

Ifu (Repatha Amgenusa 128)
A circular timer illustration showing a 30-minute interval marked, with the segment from 12 o'clock to 1 o'clock shaded in blue. The center displays "30 minutes" in bold text.*
FDA Label Image

Ifu (Repatha Amgenusa 129)

Ifu (Repatha Amgenusa 129)
An instructional illustration showing a single-dose prefilled syringe for REPATHA 140 mg/mL. A close-up highlights the window on the syringe body labeled 'Medicine,' indicating the presence of the drug solution inside the syringe.*
FDA Label Image

Ifu (Repatha Amgenusa 130)

Ifu (Repatha Amgenusa 130)
An instructional illustration showing a REPATHA 140 mg/mL prefilled pen with a magnified view highlighting the location of the lot number and expiration date on the label.*
FDA Label Image

Ifu (Repatha Amgenusa 131)

Ifu (Repatha Amgenusa 131)
An instructional anatomical illustration showing recommended injection sites for REPATHA 140 mg/mL on a human figure. Highlighted areas include the abdomen around the navel and the front of the thighs.*
FDA Label Image

Ifu (Repatha Amgenusa 132)

Ifu (Repatha Amgenusa 132)
An instructional illustration of a hand pressing down on a small swab or pad, demonstrating a step likely related to cleaning or preparing an area, possibly for an injection or medical procedure.*
FDA Label Image

Ifu (Repatha Amgenusa 133)

Ifu (Repatha Amgenusa 133)
An instructional illustration showing a hand holding a REPATHA 140 mg/mL injection pen near a vial. The yellow safety guard on the pen is clearly labeled with a warning not to touch it. The image emphasizes proper handling of the device's safety components during preparation for injection.*
FDA Label Image

Ifu (Repatha Amgenusa 134)

Ifu (Repatha Amgenusa 134)
Instructional illustration demonstrating two techniques for administering an injection with a REPATHA 140 mg/mL prefilled pen: stretching the skin and pinching the skin. The hands show how to position and hold the pen at the injection site, guiding proper use.*
FDA Label Image

Ifu (Repatha Amgenusa 135)

Ifu (Repatha Amgenusa 135)
Instructional text advising patients to be patient during injection, stating the injection may take up to 15 seconds. The text is presented in a circular format on a light blue background.*
FDA Label Image

Ifu (Repatha Amgenusa 136)

Ifu (Repatha Amgenusa 136)
An instructional illustration showing a hand holding a REPATHA 140 mg/mL prefilled pen injection device poised for subcutaneous administration with an arrow indicating downward movement. It demonstrates the proper positioning of the injection pen for use.*
FDA Label Image

Ifu (Repatha Amgenusa 137)

Ifu (Repatha Amgenusa 137)
Illustration showing a comparison of the indicator window on a REPATHA 140 mg/mL device, depicting a change in the yellow indicator fill level before and after administration or activation.*
FDA Label Image

Ifu (Repatha Amgenusa 138)

Ifu (Repatha Amgenusa 138)
An instructional illustration showing a close-up view of the REPATHA 140 mg/mL autoinjector pen window fully yellow, indicating a specific status of the device likely related to dose readiness or administration. No other text or packaging is visible.*
FDA Label Image

Ifu (Repatha Amgenusa 139)

Ifu (Repatha Amgenusa 139)
An illustration showing three almond nuts and a single adhesive bandage with multiple ventilation holes and a central pad. The label "LL29834 v1" appears on the bandage's right edge.*
FDA Label Image

Ifu (Repatha Amgenusa 140)

Ifu (Repatha Amgenusa 140)
An instructional illustration showing a red container with an open lid, a protective cap being removed, and a REPATHA 140 mg/mL single-dose injection pen. The blue arrow indicates the pen is to be placed into the container.*
FDA Label Image

Principal Display Panel (2 x 140 mg/mL Autoinjector Carton)

Principal Display Panel (2 x 140 mg/mL Autoinjector Carton)
Repatha SureClick 140 mg/mL prefilled autoinjector label showing Amgen USA Inc. as the labeler. The label includes the drug name Repatha (evolocumab), dosage strength 140 mg/mL, and indicates it is for subcutaneous use. Storage instructions specify refrigeration at 2°C to 8°C (36°F to 46°F) with warnings against freezing, shaking, and light exposure. The label also cautions about dry natural rubber content, single use only, and keeping out of reach of children.*
FDA Label Image

Principal Display Panel (1 x 140 mg/mL Autoinjector Carton)

Principal Display Panel (1 x 140 mg/mL Autoinjector Carton)
Label for REPATHA SureClick (evolocumab) Injection 140 mg/mL prefilled autoinjector by Amgen USA Inc. It indicates a single-dose autoinjector for subcutaneous use only, sterile solution with no preservative, storage instructions between 2°C to 8°C, and cautions including not to reuse and to keep out of reach of children. The label includes a barcode, a visual of the autoinjector, and regulatory information.*
FDA Label Image

Principal Display Panel (140 mg/mL Syringe Carton)

Principal Display Panel (140 mg/mL Syringe Carton)
Repatha 140 mg/mL prefilled syringe label showing evolocumab injection by Amgen USA Inc. The label indicates a 1 mL single-dose syringe intended for subcutaneous use only. Storage instructions specify refrigeration between 2°C to 8°C (36°F to 46°F) and protection from light, with warnings against freezing or shaking the product. The label includes caution and prescription-only statements, noting the solution is sterile with no preservative.*
FDA Label Image

Principal Display Panel (1 x 140 mg/mL Autoinjector Carton)

Principal Display Panel (1 x 140 mg/mL Autoinjector Carton)
Repatha SureClick 140 mg/mL prefilled autoinjector label showing the brand name, active ingredient evolocumab, strength, and dosage form. The label states it is for subcutaneous use only, includes storage instructions (refrigerate 2°C to 8°C, do not freeze or shake), and cautions against reuse. The labeler is Amgen USA Inc., and it displays a barcode and QR code linking to repathainjection.com.*
FDA Label Image

Principal Display Panel (2 x 140 mg/mL Autoinjector Carton)

Principal Display Panel (2 x 140 mg/mL Autoinjector Carton)
Repatha 140 mg/mL prefilled autoinjector label by Amgen USA Inc. The label indicates two single-dose autoinjectors containing evolocumab injection for subcutaneous use, sterile with no preservative. Storage instructions specify refrigeration at 2°C to 8°C and protection from light. The label includes usage cautions and a QR code linking to repathainjection.com.*
FDA Label Image

Principal Display Panel (1 x 140 mg/mL Autoinjector Carton)

Principal Display Panel (1 x 140 mg/mL Autoinjector Carton)
Repatha SureClick 140 mg/mL prefilled single-dose autoinjector label by Amgen USA Inc. The label indicates the injection is for subcutaneous use only, sterile with no preservative, and provides storage instructions to refrigerate the carton between 2°C to 8°C, protect from light, and avoid freezing or shaking. It includes cautionary notes that the product is not for resale, not made with natural rubber latex, and instructions to refrigerate until ready to use.*
FDA Label Image

Principal Display Panel (140 mg/mL Syringe Carton)

Principal Display Panel (140 mg/mL Syringe Carton)
Label for REPATHA (evolocumab) Injection 140 mg/mL prefilled syringe by Amgen USA Inc. The label indicates one 1 mL prefilled syringe for subcutaneous use only. Storage instructions include refrigeration at 2°C to 8°C, avoiding freezing or shaking, and protection from light. The solution is sterile with no preservative and not made with natural rubber latex.*
FDA Label Image

Principal Display Panel (140 mg/mL Prefilled Pen Carton)

Principal Display Panel (140 mg/mL Prefilled Pen Carton)
REPATHA (evolocumab) injection 140 mg/mL by Amgen USA Inc. This label shows the product name, active ingredient, strength, and injection form as a sterile solution without preservatives. The label notes it is for subcutaneous use only and includes packaging details indicating two single-dose prefilled pens. The label also highlights that enclosed patient information is required and mentions storage instructions.*
FDA Label Image

Principal Display Panel (140 mg/mL Prefilled Pen Carton)

Principal Display Panel (140 mg/mL Prefilled Pen Carton)
Label for REPATHA (evolocumab) Injection 140 mg/mL by Amgen USA Inc. The label includes an image of a single-dose prefilled pen and states it is for subcutaneous use only. It specifies the product is a sterile solution with no preservative, and that it is not made with natural rubber latex. The NDC number 72511-143-01 is shown, along with usage instructions to read before use.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.